| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of KB 5492 is the sigma receptor, where it acts as a potent and selective antagonist/inhibitor. It specifically inhibits the binding of [³H]1,3-di(2-tolyl)guanidine (DTG) to sigma receptors. The sigma receptor is a type of receptor that has been implicated in various physiological processes including modulation of ion channels, neurotransmitter release, and cell survival pathways. By blocking this receptor, KB 5492 exerts its gastroprotective effects, likely through modulation of cellular signaling pathways that regulate gastric mucosal integrity and bicarbonate secretion. The compound demonstrates high selectivity for the sigma receptor, which contributes to its specific pharmacological profile and reduced off-target effects.
|
|---|---|
| ln Vitro |
In a concentration-dependent manner, KB-5492 (0.001-100 μM) inhibits selective [3H]DTG binding [1]. The increase in 51Cr release from gastric epithelial cells generated by ethanol and acidified aspirin was considerably and concentration-dependently inhibited by KB-5492 (0.1-1 mM) [2].
In vitro studies have demonstrated that KB 5492 (0.001-100 μM) inhibits selective [³H]DTG binding in a concentration-dependent manner. The compound shows an IC50 of 3.15 μM for inhibiting specific [³H]DTG binding to sigma receptors. Additionally, ethanol- and acidified aspirin-induced increases in 51Cr release from gastric epithelial cells are significantly inhibited by KB 5492 (0.1-1 mM) in a concentration-dependent manner. This indicates that KB 5492 not only binds to sigma receptors with high affinity but also protects gastric epithelial cells from damage induced by common ulcerogenic agents. The compound's ability to inhibit both receptor binding and cellular damage suggests a direct cytoprotective effect on gastric mucosal cells. |
| ln Vivo |
KB-5492 (200 mg/kg; oral) inhibits the stomach mucosa from developing macroscopic lesions [2].
In vivo studies have shown that KB 5492 (200 mg/kg; oral administration) inhibits macroscopic lesions in the gastric mucosa. In male Sprague-Dawley rats (body weight 210-240 g) with induced gastric mucosal damage, oral administration of KB 5492 at 200 mg/kg significantly reduced lesion length compared to the control group. The compound prevents deep mucosal lesions and surface epithelial cell shedding. These findings confirm the gastroprotective efficacy of KB 5492 in animal models, supporting its potential as a therapeutic agent for gastric ulcer prevention and treatment. The oral bioavailability and efficacy at the tested dose indicate that the compound can reach its target tissues in sufficient concentrations to exert protective effects. |
| Enzyme Assay |
The cell-free assay for evaluating KB 5492 activity involves testing its ability to inhibit specific binding of [³H]1,3-di(2-tolyl)guanidine (DTG) to sigma receptors in membrane preparations. Various concentrations of KB 5492 (typically ranging from 0.001 to 100 μM) are incubated with radiolabeled DTG and receptor-containing membrane preparations. After incubation, bound radioactivity is measured, typically by filtration and scintillation counting, to determine the concentration of compound required to displace 50% of the radioligand binding (IC50). This assay allows for the quantitative assessment of the compound's affinity for the sigma receptor and its potency as a receptor antagonist.
|
| Cell Assay |
No specific cell-based assay protocol has been detailed for KB 5492 in the available literature. However, related studies have evaluated the compound's protective effects on gastric epithelial cells. In these experiments, cells are exposed to damaging agents such as ethanol or acidified aspirin, and cellular damage is quantified by measuring 51Cr release. KB 5492 (0.1-1 mM) is added to the cell culture, and its ability to inhibit the damage-induced increase in 51Cr release is assessed in a concentration-dependent manner. This approach demonstrates the compound's direct cytoprotective effects on gastric epithelial cells, independent of its receptor binding activity.
|
| Animal Protocol |
Animal/Disease Models: Male SD (SD (Sprague-Dawley)) rats, body weight 210-240 g, induced gastric mucosal damage [2]
Doses: 200 mg/kg Route of Administration: po (oral gavage) Experimental Results: Compared with the control, the lesion length was shortened. Prevent deep mucosal lesions and surface epithelial cell shedding. In vivo efficacy of KB 5492 is evaluated using a rat model of gastric mucosal damage. Male Sprague-Dawley rats weighing 210-240 g are used for the study. Gastric mucosal damage is induced using appropriate ulcerogenic agents. KB 5492 is administered orally at a dose of 200 mg/kg. Following the treatment period, gastric tissues are examined and lesion length is measured. The compound's protective effect is assessed by comparing the lesion length and severity in treated animals versus control animals. Histological examination may also be performed to evaluate the extent of mucosal protection and prevention of epithelial cell shedding. |
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is publicly available for KB 5492. As a small molecule with a molecular weight of 546.57 and formula C27H34N2O10, it is expected to have reasonable oral absorption based on its demonstrated oral activity in animal models. The compound has a logP of 2.031, indicating moderate lipophilicity which may contribute to favorable membrane permeability. It has 2 hydrogen bond donors and 12 hydrogen bond acceptors, with 12 rotatable bonds. The compound shows good stability as a powder and can be stored under appropriate conditions for extended periods.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data is publicly available for KB 5492. Preclinical safety assessment would typically include acute and repeated-dose toxicity studies in rodents, as well as hERG channel evaluation for cardiac safety, consistent with standard drug development practices. The compound's selectivity for sigma receptors may contribute to a favorable safety profile, as off-target effects would be minimized. However, comprehensive toxicological evaluation would be required before any therapeutic application could be considered. The compound is currently for research use only and not intended for human therapeutic use.
|
| References |
|
| Additional Infomation |
KB 5492 (also known as 1-(3,4,5-trimethoxybenzyl)-4-((4-methoxyphenyl)oxycarbonylmethyl)piperazine) has a molecular weight of 546.57 and formula C27H34N2O10. It is available as KB-5492 anhydrous and has a purity suitable for research applications. The compound has a boiling point of 553.2ºC at 760 mmHg, a flash point of 288.3ºC, and a vapor pressure of 2.8E-12mmHg at 25°C. The molecular complexity is rated at 639. No clinical trial or approved drug status has been identified; this compound remains a research tool for studying sigma receptor function and gastric protection. It is classified as an anti-ulcer agent and sigma receptor inhibitor.
|
| Molecular Formula |
C27H34N2O10
|
|---|---|
| Molecular Weight |
546.57
|
| Exact Mass |
546.221
|
| CAS # |
129200-10-8
|
| Related CAS # |
KB-5492 free base;113594-64-2
|
| PubChem CID |
6439276
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
553.2ºC at 760 mmHg
|
| Flash Point |
288.3ºC
|
| Vapour Pressure |
2.8E-12mmHg at 25°C
|
| LogP |
2.031
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
39
|
| Complexity |
639
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)OC(=O)CN2CCN(CC2)CC3=CC(=C(C(=C3)OC)OC)OC.C(=C/C(=O)O)\C(=O)O
|
| InChi Key |
JUOYRBCKLAPYBI-WLHGVMLRSA-N
|
| InChi Code |
InChI=1S/C23H30N2O6.C4H4O4/c1-27-18-5-7-19(8-6-18)31-22(26)16-25-11-9-24(10-12-25)15-17-13-20(28-2)23(30-4)21(14-17)29-3;5-3(6)1-2-4(7)8/h5-8,13-14H,9-12,15-16H2,1-4H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
|
| Chemical Name |
(E)-but-2-enedioic acid;(4-methoxyphenyl) 2-[4-[(3,4,5-trimethoxyphenyl)methyl]piperazin-1-yl]acetate
|
| Synonyms |
KB5492; KB-5492; KB 5492
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~457.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 6: ≥ 2.08 mg/mL (3.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8296 mL | 9.1480 mL | 18.2959 mL | |
| 5 mM | 0.3659 mL | 1.8296 mL | 3.6592 mL | |
| 10 mM | 0.1830 mL | 0.9148 mL | 1.8296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
